Olaratumab, previously identified as LY3012207 and subsequently recognized as IMC-3G3, represents a unique novel monoclonal antibody therapeutic agent targeting the tumor-associated glycoprotein podoplanin PDPN gp38. https://imc3g3995692.wikiexpression.com/user